SG11202100883SA - Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use - Google Patents

Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use

Info

Publication number
SG11202100883SA
SG11202100883SA SG11202100883SA SG11202100883SA SG11202100883SA SG 11202100883S A SG11202100883S A SG 11202100883SA SG 11202100883S A SG11202100883S A SG 11202100883SA SG 11202100883S A SG11202100883S A SG 11202100883SA SG 11202100883S A SG11202100883S A SG 11202100883SA
Authority
SG
Singapore
Prior art keywords
nkg2d
methods
specific binding
binding proteins
bind bcma
Prior art date
Application number
SG11202100883SA
Inventor
Mitchell Bigelow
Gregory P Chang
Ann F Cheung
Asya Grinberg
William Haney
Nicolai Wagtmann
Bradley M Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of SG11202100883SA publication Critical patent/SG11202100883SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202100883SA 2018-08-08 2019-08-08 Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use SG11202100883SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716207P 2018-08-08 2018-08-08
PCT/US2019/045632 WO2020033630A1 (en) 2018-08-08 2019-08-08 Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use

Publications (1)

Publication Number Publication Date
SG11202100883SA true SG11202100883SA (en) 2021-02-25

Family

ID=69413838

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100883SA SG11202100883SA (en) 2018-08-08 2019-08-08 Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use

Country Status (19)

Country Link
US (2) US20210317223A1 (en)
EP (1) EP3833392A4 (en)
JP (1) JP2021533169A (en)
KR (1) KR20210043602A (en)
CN (1) CN112823022A (en)
AR (1) AR114544A1 (en)
AU (1) AU2019318083A1 (en)
BR (1) BR112021002072A2 (en)
CA (1) CA3108427A1 (en)
CL (1) CL2021000316A1 (en)
CO (1) CO2021001410A2 (en)
EA (1) EA202190468A1 (en)
IL (1) IL280512A (en)
MA (1) MA53293A (en)
MX (1) MX2021001524A (en)
PE (1) PE20211860A1 (en)
SG (1) SG11202100883SA (en)
TW (1) TW202019479A (en)
WO (1) WO2020033630A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008336A (en) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor.
US20230364230A1 (en) * 2020-09-11 2023-11-16 Engmab Sàrl Combination therapy for cancer
CN117881702A (en) * 2021-08-03 2024-04-12 山东先声生物制药有限公司 CD16 antibody and application thereof
US20230203202A1 (en) * 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100490A1 (en) * 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
EP3670535A1 (en) * 2015-08-03 2020-06-24 EngMab Sàrl Monoclonal antibodies against bcma
CA3016563A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US11851491B2 (en) * 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
EP3579876A4 (en) * 2017-02-10 2020-11-18 Dragonfly Therapeutics, Inc. Proteins binding bcma, nkg2d and cd16

Also Published As

Publication number Publication date
KR20210043602A (en) 2021-04-21
PE20211860A1 (en) 2021-09-21
AR114544A1 (en) 2020-09-16
TW202019479A (en) 2020-06-01
MX2021001524A (en) 2021-04-19
IL280512A (en) 2021-03-25
JP2021533169A (en) 2021-12-02
CA3108427A1 (en) 2020-02-13
MA53293A (en) 2021-11-17
CL2021000316A1 (en) 2021-07-30
CO2021001410A2 (en) 2021-05-10
WO2020033630A1 (en) 2020-02-13
EP3833392A4 (en) 2022-05-18
EP3833392A1 (en) 2021-06-16
US20220089760A1 (en) 2022-03-24
EA202190468A1 (en) 2021-07-06
AU2019318083A1 (en) 2021-02-25
CN112823022A (en) 2021-05-18
US20210317223A1 (en) 2021-10-14
BR112021002072A2 (en) 2021-06-01

Similar Documents

Publication Publication Date Title
IL268567A (en) Proteins binding bcma, nkg2d and cd16
IL276778A (en) Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
IL281305A (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
IL280656A (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
IL268755A (en) Proteins binding her2, nkg2d and cd16
IL280512A (en) Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
IL281323A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
IL268790A (en) Proteins binding cd33, nkg2d and cd16
IL270794A (en) A protein binding nkg2d, cd16 and ror1 or ror2
IL273206A (en) Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
IL279201A (en) Multi-specific binding proteins and methods of use thereof
IL268768A (en) Proteins binding gd2, nkg2d and cd16
IL272374A (en) Proteins binding nkg2d, cd16 and flt3
IL272706A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
IL292261A (en) Proteins binding nkg2d, cd16 and flt3
IL270803A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
IL268574A (en) Proteins binding psma, nkg2d and cd16
IL268766A (en) Proteins binding cd123, nkg2d and cd16
IL270801A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
ZA201905273B (en) Proteins binding psma, nkg2d and cd16